Intuitive Surgical, Inc. (NASDAQ:ISRG – Get Free Report) CEO Gary S. Guthart sold 27,385 shares of the company’s stock in a transaction that occurred on Thursday, October 26th. The stock was sold at an average price of $260.11, for a total transaction of $7,123,112.35. Following the completion of the transaction, the chief executive officer now owns 23,551 shares in the company, valued at $6,125,850.61. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Intuitive Surgical Price Performance
Shares of NASDAQ:ISRG opened at $258.98 on Friday. The stock has a market cap of $91.18 billion, a P/E ratio of 60.94, a P/E/G ratio of 4.41 and a beta of 1.30. The firm has a fifty day moving average price of $290.55 and a 200 day moving average price of $305.61. Intuitive Surgical, Inc. has a 1-year low of $222.65 and a 1-year high of $358.07.
Intuitive Surgical (NASDAQ:ISRG – Get Free Report) last issued its quarterly earnings results on Thursday, October 19th. The medical equipment provider reported $1.46 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.06. The firm had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.77 billion. Intuitive Surgical had a net margin of 22.14% and a return on equity of 12.91%. Intuitive Surgical’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.90 EPS. Sell-side analysts expect that Intuitive Surgical, Inc. will post 4.54 EPS for the current fiscal year.
Institutional Trading of Intuitive Surgical
Wall Street Analysts Forecast Growth
ISRG has been the topic of several recent research reports. TheStreet raised shares of Intuitive Surgical from a “c+” rating to a “b” rating in a research note on Monday, July 24th. Wells Fargo & Company cut their target price on shares of Intuitive Surgical from $386.00 to $363.00 and set an “overweight” rating on the stock in a research note on Friday, October 20th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $355.00 target price on shares of Intuitive Surgical in a research note on Friday, October 20th. Morgan Stanley cut their target price on shares of Intuitive Surgical from $330.00 to $300.00 and set an “equal weight” rating on the stock in a research note on Monday, October 23rd. Finally, Mizuho increased their price objective on shares of Intuitive Surgical from $300.00 to $370.00 in a research report on Monday, July 17th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $342.20.
About Intuitive Surgical
Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.
- Five stocks we like better than Intuitive Surgical
- Canada Bond Market Holiday: How to Invest and Trade
- Can casino stocks win big if economy slows?
- How to Invest in Cannabis, Step by Step
- Amazon comes to a boil; complete price reversal in sight
- 3 Warren Buffett Stocks to Buy Now
- Ford charts new path for EVs with focus on cost efficiency
Receive News & Ratings for Intuitive Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuitive Surgical and related companies with MarketBeat.com's FREE daily email newsletter.